SRTPUTL4        ;BIR/SJA - RISK ASSESSMENT UTILITY ;05/15/08
        ;;3.0; Surgery ;**167**;24 Jun 93;Build 27
        N SRZZ,SRXX,SRX1
        S SRZ=0 F  S SRZ=$O(SRYY(139.5,SRTPP,SRZ)) Q:'SRZ  D
        .I $P(SRYY(139.5,SRTPP,SRZ,"I"),"^")="" S SRZ1=$P($G(SRYY(139.5,SRTPP,SRZ,"I")),"^",2) D TR S X=$T(@SRP),SRFLD=$P(X,";;",2),SRX(SRMM,SRZ)=$P(SRFLD,"^",2)_"^"_SRZ1
        .I $P(SRYY(139.5,SRTPP,SRZ,"I"),"^")="NS" S SRZ1=$P($G(SRYY(139.5,SRTPP,SRZ,"I")),"^",2) D TR S X=$T(@SRP),SRFLD=$P(X,";;",2),SRDT=$P(SRFLD,"^",4) S:SRDT'="" SRLR(SRDT)=""
        S SRDT=0 F  S SRDT=$O(SRLR(SRDT)) Q:'SRDT  D
        .S SRZ=0 F  S SRZ=$O(SRX(SRZ)) Q:'SRZ  S SRZ1=0 F  S SRZ1=$O(SRX(SRZ,SRZ1)) Q:'SRZ1  I SRZ1=SRDT K SRX(SRZ,SRZ1)
        Q
TR      S SRP=SRZ1,SRP=$TR(SRP,"1234567890.","ABCDEFGHIJP")
        Q
GET     S X=$T(@J)
        Q
C       ;;3^VACO ID
D       ;;4^Recipient Height^
E       ;;5^Recipient Weight^
I       ;;9^IVIG Recipient^
AJ      ;;10^Recipient ABO Blood Type^
AA      ;;11^Date Placed on Waiting List^
AB      ;;12^Recipient CMV^
AC      ;;13^Recipient HLA-A Typing^
AD      ;;14^Recipient HLA-B Typing^
AE      ;;15^Recipient HLA-C Typing^
AF      ;;16^Recipient HLA-BW Typing^
AG      ;;17^Recipient HLA-DR Typing^
AH      ;;18^Recipient HLA-DQ Typing^
AI      ;;19^Transplant Comments^
BJ      ;;20^Acetaminophen Toxicity^
BA      ;;21^Acute Liver Failure^
BB      ;;22^Lung Cancer^
BC      ;;23^Alcoholic Cirrhosis^
BD      ;;24^Alpha 1 Anti-Trypsin Deficiency^
BE      ;;25^Bronchiectasis^
BF      ;;26^Glomerular Sclerosis/Nephritis^
BG      ;;27^Graft Failure^
BH      ;;28^HBV Cirrhosis (Hepatitis B)^
BI      ;;29^HCC (Hepatocellular CA)^
CJ      ;;30^HCV Cirrhosis (Hepatitis C)^
CA      ;;31^Donor Height^
CB      ;;32^Interstitial Lung Disease^
CC      ;;33^Membranous Nephropathy^
CD      ;;34^Metabolic^
CE      ;;35^NASH ^
CF      ;;36^Donor Weight^
CG      ;;37^Polycystic Disease^
CH      ;;38^Primary Biliary Cholangitis^
CI      ;;39^Primary Sclerosing Cholangitis^
DJ      ;;40^Pulmonary Fibrosis^
DA      ;;41^Pulmonary Hypertension^
DB      ;;42^Renal Cancer^
DC      ;;43^Sarcoidosis^
DD      ;;44^Donor Race^
DE      ;;45^Donor Gender^
DF      ;;46^Donor Age^
DG      ;;47^Biliary Stricture^
DH      ;;48^Donor ABO Blood Type^
DI      ;;49^Donor CMV^
EJ      ;;50^LAS Score at Listing^
EA      ;;51^LAS Score at Transplant^
EB      ;;52^MELD Score at Listing^
EC      ;;53^Biologic MELD score at listing^
ED      ;;54^MELD score at transplant^
EE      ;;55^Biologic MELD score at transplant^
EF      ;;56^Bile Leak^
EG      ;;57^UNOS Status at time of Transplant^
EH      ;;58^UNOS Status at time of Listing^
EI      ;;59^Diabetic Retinopathy^
FJ      ;;60^Diabetic Neuropathy^
FA      ;;61^Cardiac Disease (CAD, AF, EF<50%)^
FB      ;;62^Inotrope Dependent Pre-Transplant^
FC      ;;63^Medical Center Division^
FD      ;;64^Donor HLA-A Typing^
FE      ;;65^Donor HLA-B Typing^
FF      ;;66^Donor HLA-C Typing^
FG      ;;67^Donor HLA-BW Typing^
FH      ;;68^Crossmatch D/R^
FI      ;;69^Deceased Donor^
GJ      ;;70^Donor Date of Birth^
GA      ;;71^Elevated PAP^
GB      ;;72^Donor HLA-DQ Typing^
GC      ;;73^Donor HLA-DR Typing^
GD      ;;74^Pulmonary Hypertension / Elevated PAP^
GE      ;;75^Liver Disease^
GF      ;;76^COPD ^
GG      ;;77^Donor Substance Abuse^
GH      ;;78^Porto Pulmonary Hypertension^
GI      ;;79^History of Bleeding Esophageal and/or Gastric Varices^
HJ      ;;80^Pre-Transplant Malignancy^
HA      ;;81^History of Preop Transplant Skin Malignancy^
HB      ;;82^History of Other Pre-Transplant Malignancy^
HC      ;;83^Recipient Substance Abuse^
HD      ;;84^Active Infection for PSC^
HE      ;;85^Warm Ischemia Time For Organ^
HF      ;;86^Acute or Chronic Encephalopathy^
HG      ;;87^Cold Ischemia Time for Organ^
HH      ;;88^History of Ascites^
HI      ;;89^Total Ischemia Time for Organ^
IJ      ;;90^Non-Compliance (Med and Diet)^
IA      ;;91^On Methadone^
IB      ;;92^Post Transplant Prophylaxis for TB/Antimycobacterial Treatment^
ID      ;;94^Rejection^
IE      ;;95^IgA Nephropathy^
IF      ;;96^Calcineurin Inhibitor Toxicity^
IG      ;;97^Lithium Toxicity^
IH      ;;98^Obstructive Uropathy from BPH^
II      ;;99^Autoimmune Hepatitis^
AJJ     ;;100^Cryptogenic Cirrhosis^
AJA     ;;101^Chronic Rejection^
AJB     ;;102^Hepatic Artery Thrombosis^
AJC     ;;103^Living Donor^
AJD     ;;104^Donor with Malignancy^
AJE     ;;105^Primary Non-Function^
AJF     ;;106^Secondary Sclerosing Cholangitis^
AJG     ;;107^Toxic Exposure^
AJH     ;;108^HIV + (positive)^
AJI     ;;109^Post Transplant Prophylaxis for CMV/Antiviral Treatment^
AAJ     ;;110^Post Transplant Prophylaxis for PCP/Antibacterial Treatment^
AAA     ;;111^Portal Vein Thrombosis^
AAB     ;;112^Other Cardiomyopathy^
AAC     ;;113^Lung Disease^
AAD     ;;114^Renal Impairment (Serum Creatinine >1.5)^
AAE     ;;115^Active Infection Requiring Antibiotics^
AAF     ;;116^Bleeding/Transfusions^
AAG     ;;117^Pneumonia^
AAH     ;;118^On Ventilator > 48 Hours^
AAI     ;;119^Cardiac Arrest Requiring CPR^
ABJ     ;;120^Psychosis^
ABA     ;;121^Stroke/CVA^
ABB     ;;122^Coma Greater than 24 Hours Postop (Y/N)^
ABC     ;;123^Superficial Incisional SSI^
ABD     ;;124^Deep Incisional SSI^
ABE     ;;125^Systemic Sepsis^
ABF     ;;126^Return to Surgery within 30 days^
ABG     ;;127^Seizures^
ABH     ;;128^Emphysema^
ABI     ;;129^Other Diagnosis^
ACJ     ;;130^New Mechanical Circulatory Support^
ACA     ;;131^Preop Functional Health Status^
ACB     ;;132^Peripheral Vascular Disease^
ACC     ;;133^Graft Failure Date^
ACD     ;;134^Pancreas^
ACE     ;;135^Glucose at Time of Listing^
ACF     ;;136^C-peptide at Time of Listing^
ACG     ;;137^Pancreatic Duct Anastomosis^
ACH     ;;138^Glucose Post Transplant^
ACI     ;;139^Amylase Post Transplant^
ADJ     ;;140^Lipase Post Transplant^
ADA     ;;141^Insulin Required Post transplant^
ADB     ;;142^Oral Hypoglycemics Required Post Transplant^
ADC     ;;143^PRA at Listing^
ADD     ;;144^PRA at Transplant^
ADE     ;;145^Hypertension Requiring Meds^
ADF     ;;146^Transfusion >4 RBC Units^
ADG     ;;147^Diabetes Mellitus^
ADH     ;;148^Reoperation for Bleeding^
ADI     ;;149^Amiodarone Use^
AEJ     ;;150^Heparin Sensitivity^
AEA     ;;151^Hyperlipidemia History^
AEB     ;;152^Ventricular Tachycardia^
AEC     ;;153^Prior Blood Transfusion^
AED     ;;154^Creatinine on Day of Transplant^
AEE     ;;155^Dilated Cardiomyopathy^
AEF     ;;156^Coronary Artery Disease^
AEG     ;;157^Ischemic Cardiomyopathy^
AEH     ;;158^Alcoholic Cardiomyopathy^
AEI     ;;159^Valvular Cardiomyopathy^
AFJ     ;;160^Idiopathic Cardiomyopathy^
AFA     ;;161^Viral Cardiomyopathy^
AFB     ;;162^Peripartum Cardiomyopathy^
AFC     ;;163^PVR Before Vasodilation^
AFD     ;;164^PVR After Vasodilation^
AFE     ;;165^LVEF % ^
AFF     ;;166^PRA %^
AFG     ;;167^PA Systolic Pressure^
AFH     ;;168^PAW Mean Pressure^
AFI     ;;169^FEV1 ^
AGJ     ;;170^Date of Death^
AGA     ;;171^Current Smoker^
AGB     ;;172^Prior MI^
AGC     ;;173^Number of Prior Heart Surgeries^
AGD     ;;174^Cerebral Vascular Disease^
AGE     ;;175^Congestive Heart Failure (CHF)^
AGF     ;;176^IV NTG within 48 Hours^
AGG     ;;177^Current Digoxin Use^
AGH     ;;178^Current Diuretic Use^
AGI     ;;179^Preoperative Circulatory Device^
AHA     ;;181^Assessment Status^
AHB     ;;182^Transplant Type^
AHD     ;;184^Date Transmitted^
AHE     ;;185^VA or Non-VA Indicator^
AHG     ;;187^Date Started Dialysis^
AHI     ;;189^Tracheostomy^
AIJ     ;;190^Mediastinitis^
AIA     ;;191^Renal Failure Requiring Dialysis^
AIB     ;;192^Perioperative MI^
AIC     ;;193^Operative Death^
AIG     ;;197^Plasmapheresis^
        Q
